







an Open Access Journal by MDPI

# **Proton Therapy for CNS Tumors**

Guest Editors:

## **Prof. Dr. Beate Timmermann**

Department of Particle Therapy, West German Proton Therapy Centre Essen (WPE), University Hospital Essen, German Cancer Consortium (DKTK), 45122 Essen, Germany

### Dr. Julie A. Bradley

Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA

Deadline for manuscript submissions:

closed (31 December 2022)

# **Message from the Guest Editors**

Radiotherapy is an important and highly effective part of modern multimodality management of CNS tumors. However, radiotherapy is known to cause a broad range of adverse effects, potentially having a significant negative impact on quality of life. Thus, strategies that mitigate late effects are needed. With regard to radiotherapy, techniques are attractive when able to better protect normal tissue and critical organs of risk. Due to its particular physical characteristics, Proton therapy (PT) can achieve high dose conformality to the target volume while sparing normal tissue. Important technological advances have managed to make PT more robust and deliverable to a huge variety of tumor entities. PT is often preferred in tumors sites in the vicinity of particularly vulnerable tissue and in tumors requiring high radiation doses. Therefore, CNS and base of skull tumors of the CNS are the predominant diagnoses in the majority of proton facilities and clinical evidence is increasing. This Special Issue on proton therapy for CNS tumors will highlight the role of PT in CNS tumors, covering various clinical, physical, and biological aspects.













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

# **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

### **Contact Us**